Literature DB >> 21531004

Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study.

Evgeny Yakirevich1, Andres Matoso, Edmond Sabo, Li J Wang, Rosemarie Tavares, Patricia Meitner, David J Morris, Gyan Pareek, Ronald A Delellis, Murray B Resnick.   

Abstract

Glucocorticoid receptors mediate the action of steroid hormones in a variety of tissues, including the kidney. Our goal was to determine the expression pattern and prognostic significance of glucocorticoid receptor in renal cell neoplasms. Paraffin-embedded microarrays from 200 patients with RCNs including 147 clear cell renal cell carcinomas, 23 papillary, 16 chromophobe renal cell carcinoma, and 14 oncocytomas were analyzed for glucocorticoid receptor expression by immunohistochemistry. Glucocorticoid receptor expression was also quantitated by real-time reverse transcriptase polymerase chain reaction in 45 cases (33 clear cell renal cell carcinomas, 5 chromophobe renal cell carcinomas, and 3 oncocytomas). Strong nuclear glucocorticoid receptor expression was present in normal glomeruli and in the proximal convoluted tubules. Nuclear glucocorticoid receptor expression was found in most clear cell renal cell carcinomas (66%), in 26% of papillary renal cell carcinomas, and in only 6% of chromophobe renal cell carcinomas and 14% of oncocytoma (P < .005). Within the clear cell renal cell carcinoma group, most positive cases (87%) demonstrated strong immunoreactivity (2+ and 3+), whereas only 1 papillary renal cell carcinoma, 1 chromophobe renal cell carcinoma, and none of the oncocytomas showed strong expression. Glucocorticoid receptor α messenger RNA expression was significantly higher in clear cell renal cell carcinoma than in chromophobe renal cell carcinoma, oncocytoma, or in the normal kidney. Significantly more frequent glucocorticoid receptor expression was associated with tumors of low nuclear grade (Fuhrman grade 1 and 2) and low stage (stages 1 and 2; P = .0068 and P = .0002). Survival analysis revealed a significant direct correlation between glucocorticoid receptor expression and overall survival in clear cell renal cell carcinoma (P = .01). In summary, strong glucocorticoid receptor expression was most commonly seen in clear cell renal cell carcinoma and only rarely seen in other subtypes. The glucocorticoid receptor expression pattern in RCNs seems to reflect the histogenetic origin of clear cell renal cell carcinoma from the proximal nephron. Finally, glucocorticoid receptor expression proved to be a marker of less aggressive behavior in clear cell renal cell carcinoma.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531004     DOI: 10.1016/j.humpath.2011.01.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors.

Authors:  Sahyun Pak; Wansuk Kim; Yunlim Kim; Cheryn Song; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-10       Impact factor: 4.553

2.  Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression.

Authors:  Hitoshi Ishiguro; Takashi Kawahara; Yichun Zheng; George J Netto; Hiroshi Miyamoto
Journal:  Am J Clin Pathol       Date:  2014-08       Impact factor: 2.493

3.  Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer.

Authors:  Sahyun Pak; Jungyo Suh; Seo Young Park; Yunlim Kim; Yong Mee Cho; Hanjong Ahn
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

4.  Cortisol biosynthesis in the human ocular surface innate immune response.

Authors:  Radhika Susarla; Lei Liu; Elizabeth A Walker; Iwona J Bujalska; Jawaher Alsalem; Geraint P Williams; Sreekanth Sreekantam; Angela E Taylor; Mohammad Tallouzi; H Susan Southworth; Philip I Murray; Graham R Wallace; Saaeha Rauz
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.